Communicable E5 - Beauty is in the 'I' of the beholder: EUCAST updates
The ‘I’ (intermediate susceptibility) in a EUCAST-guided antibiogram never meant impending resistance to your antibiotic. It was never meant to make you find the one ‘S’ (invariably a carbapenem) and ...
15 Juli 202438min
Communicable E4 - The BLING-3 trial & continuous beta-lactam infusion: should these results change your practice?
Hosts Angela Huttner & Erin McCreary welcome Prof. David Paterson (Singapore) and Prof. Josh Davis (Newcastle, Australia) to discuss the design and results of the BLING-3 trial, which compared continu...
1 Juli 202444min
Communicable E3 - The new WHO Priority Pathogens List: which bugs to target first?
What are WHO's most wanted bacterial pathogens in 2024? Hosts Angela Huttner & Oana Sandulescu welcome guests Dr. Hatim Sati of the World Health Organisation (WHO) and Dr. Erin Duffy (CARB-X) to discu...
17 Juni 202442min
Communicable E2 - Phage therapy: does it work and will we have access?
In this episode, hosts Josh Davis (Newcastle, Australia) and Angela Huttner (Geneva, Switzerland) interview the phage ‘microbiologist-clinician duo’, Drs. Shawna McCallin and Lorenz Leitner (Balgrist ...
3 Juni 202454min
Communicable E1 - Late-breaker clinical trial results from ESCMID Global 2024: Should they change your practice?
CMI Communications editors Angela Huttner, Marc Bonten, and Erin McCreary discuss late-breaker clinical trials presented at ESCMID Global (ECCMID) in Barcelona, providing insights into the trials’ des...
10 Maj 202458min
